TargetMol

Ipilimumab

Product Code:
 
TAR-T9906
Product Group:
 
Primary Antibodies
Supplier:
 
TargetMol
Antibody Clonality:
 
Monoclonal
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T9906-1mg1mg£436.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9906-5mg5mg£922.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9906-10mg10mg£1,219.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9906-25mg25mg£1,773.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9906-50mg50mg£2,368.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9906-100mg100mg£3,163.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Ipilimumab anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.
CAS:
477202-00-9
Formula:
0
Molecular Weight:
148 kDa
Purity:
0.98
SMILES:
0

References

Selby MJ, et al. Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology. PLoS One. 2016 Sep 9;11(9):e0161779 Giuseppe Tridente. Adverse Events with Biomedicines, 2013. Hu-Lieskovan S, et al. Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol. 2014 Jul 20;32(21):2248-54. Yano H, et al. Ipilimumab augments antitumor activity of bispecific antibody-armed T cells. J Transl Med. 2014 Jul 9;12:191. Cui J, Yu J, Xu H, et al. Autophagy-lysosome inhibitor chloroquine prevents CTLA-4 degradation of T cells and attenuates acute rejection in murine skin and heart transplantation[J]. Theranostics. 2020, 10(18): 8051. Cui J, Yu J, Xu H, et al. Autophagy-lysosome inhibitor chloroquine prevents CTLA-4 degradation of T cells and attenuates acute rejection in murine skin and heart transplantation. Theranostics. 2020, 10(18): 8051.